Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

About Cabazitaxel API

Product
  • Therapeutic Category Oncology

  • CAS Number

    183133-96-2

  • API Technology

    Synthetic

  • Dose Form

    Injectable

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, EUDMF, Russia DMF, Kenya

Mechanism of Action

Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.

Indication

JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Cabazitaxel
Select Regulatory Requirements
Select Purpose

Related APIs

Bortezomib

Oncology

arrow

Cabazitaxel

Oncology

arrow

Cabozantinib S-Malate

Oncology

arrow

Capecitabine

Oncology

arrow

Carfilzomib

Oncology

arrow

Decitabine

Oncology

arrow

Deucravacitinib

Oncology

arrow

Eribulin Mesylate

Oncology

arrow

Capivasertib

Oncology

arrow

Abiraterone Acetate

Oncology

arrow

Apalutamide (Amorphous & Form B)

Oncology

arrow

Azacitidine

Oncology

arrow

Cabozantinib Hydrochloride

Oncology

arrow

Bendamustine Hydrochloride(盐酸苯达莫司汀)

Oncology

arrow

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.